NI201800043A - Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 - Google Patents
Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1Info
- Publication number
- NI201800043A NI201800043A NI201800043A NI201800043A NI201800043A NI 201800043 A NI201800043 A NI 201800043A NI 201800043 A NI201800043 A NI 201800043A NI 201800043 A NI201800043 A NI 201800043A NI 201800043 A NI201800043 A NI 201800043A
- Authority
- NI
- Nicaragua
- Prior art keywords
- dyrk1
- clk1
- imidazo
- pyridine
- new derivatives
- Prior art date
Links
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 title 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 title 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 title 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 title 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
(Fórmula I) Compuestos de fórmula (I): útiles para el tratamiento de cáncer, trastornos neurodegenerativos y trastornos metabólicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1559252A FR3041639B1 (fr) | 2015-09-30 | 2015-09-30 | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201800043A true NI201800043A (es) | 2018-06-21 |
Family
ID=54979755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201800043A NI201800043A (es) | 2015-09-30 | 2018-03-23 | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20180273528A1 (es) |
| EP (1) | EP3356363A1 (es) |
| JP (1) | JP2018535931A (es) |
| KR (1) | KR20180054858A (es) |
| CN (1) | CN108137581A (es) |
| AU (1) | AU2016333505A1 (es) |
| BR (1) | BR112018006157A2 (es) |
| CA (1) | CA2999935A1 (es) |
| CL (1) | CL2018000783A1 (es) |
| CO (1) | CO2018003473A2 (es) |
| CR (1) | CR20180181A (es) |
| CU (1) | CU20180028A7 (es) |
| DO (1) | DOP2018000083A (es) |
| EA (1) | EA201890821A1 (es) |
| EC (1) | ECSP18023253A (es) |
| FR (1) | FR3041639B1 (es) |
| HK (1) | HK1255804A1 (es) |
| IL (1) | IL258341A (es) |
| MA (1) | MA43020A (es) |
| MX (1) | MX2018003860A (es) |
| NI (1) | NI201800043A (es) |
| PE (1) | PE20181331A1 (es) |
| PH (1) | PH12018500650A1 (es) |
| SV (1) | SV2018005657A (es) |
| TN (1) | TN2018000090A1 (es) |
| WO (1) | WO2017055530A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12528810B2 (en) | 2018-03-01 | 2026-01-20 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of DYRK/CLK and uses thereof |
| CN108822103A (zh) * | 2018-07-28 | 2018-11-16 | 刘凤娟 | 一种咪唑并[4,5-b]吡啶化合物及其制备方法和应用 |
| CA3118093A1 (en) * | 2018-09-28 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Small molecule inhibitors of dyrk1/clk and uses thereof |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN114786673A (zh) | 2019-09-11 | 2022-07-22 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2901334A1 (en) * | 2013-03-13 | 2014-10-02 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
-
2015
- 2015-09-30 FR FR1559252A patent/FR3041639B1/fr not_active Expired - Fee Related
-
2016
- 2016-09-30 HK HK18114643.2A patent/HK1255804A1/zh unknown
- 2016-09-30 CR CR20180181A patent/CR20180181A/es unknown
- 2016-09-30 KR KR1020187012175A patent/KR20180054858A/ko not_active Withdrawn
- 2016-09-30 MA MA043020A patent/MA43020A/fr unknown
- 2016-09-30 WO PCT/EP2016/073395 patent/WO2017055530A1/en not_active Ceased
- 2016-09-30 CN CN201680058054.0A patent/CN108137581A/zh not_active Withdrawn
- 2016-09-30 TN TNP/2018/000090A patent/TN2018000090A1/en unknown
- 2016-09-30 EP EP16774682.5A patent/EP3356363A1/en not_active Withdrawn
- 2016-09-30 EA EA201890821A patent/EA201890821A1/ru unknown
- 2016-09-30 US US15/763,248 patent/US20180273528A1/en not_active Abandoned
- 2016-09-30 JP JP2018516194A patent/JP2018535931A/ja active Pending
- 2016-09-30 MX MX2018003860A patent/MX2018003860A/es unknown
- 2016-09-30 PE PE2018000443A patent/PE20181331A1/es unknown
- 2016-09-30 AU AU2016333505A patent/AU2016333505A1/en not_active Abandoned
- 2016-09-30 CA CA2999935A patent/CA2999935A1/en not_active Abandoned
- 2016-09-30 BR BR112018006157A patent/BR112018006157A2/pt not_active Application Discontinuation
- 2016-09-30 CU CUP2018000028A patent/CU20180028A7/es unknown
-
2018
- 2018-03-22 SV SV2018005657A patent/SV2018005657A/es unknown
- 2018-03-23 NI NI201800043A patent/NI201800043A/es unknown
- 2018-03-23 PH PH12018500650A patent/PH12018500650A1/en unknown
- 2018-03-25 IL IL258341A patent/IL258341A/en unknown
- 2018-03-26 EC ECIEPI201823253A patent/ECSP18023253A/es unknown
- 2018-03-26 CL CL2018000783A patent/CL2018000783A1/es unknown
- 2018-03-27 DO DO2018000083A patent/DOP2018000083A/es unknown
- 2018-03-28 CO CONC2018/0003473A patent/CO2018003473A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255804A1 (zh) | 2019-08-23 |
| SV2018005657A (es) | 2018-07-31 |
| CR20180181A (es) | 2018-06-22 |
| CL2018000783A1 (es) | 2018-09-21 |
| TN2018000090A1 (en) | 2019-07-08 |
| PE20181331A1 (es) | 2018-08-20 |
| CO2018003473A2 (es) | 2018-07-10 |
| EA201890821A1 (ru) | 2018-10-31 |
| ECSP18023253A (es) | 2018-04-30 |
| MX2018003860A (es) | 2018-08-16 |
| KR20180054858A (ko) | 2018-05-24 |
| IL258341A (en) | 2018-05-31 |
| CA2999935A1 (en) | 2017-04-06 |
| FR3041639A1 (es) | 2017-03-31 |
| DOP2018000083A (es) | 2018-10-15 |
| BR112018006157A2 (pt) | 2018-10-09 |
| FR3041639B1 (fr) | 2019-01-25 |
| WO2017055530A1 (en) | 2017-04-06 |
| PH12018500650A1 (en) | 2018-10-01 |
| CU20180028A7 (es) | 2018-07-05 |
| US20180273528A1 (en) | 2018-09-27 |
| EP3356363A1 (en) | 2018-08-08 |
| MA43020A (fr) | 2018-08-08 |
| CN108137581A (zh) | 2018-06-08 |
| AU2016333505A1 (en) | 2018-04-19 |
| JP2018535931A (ja) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| NI201800043A (es) | Nuevos derivados de imidazo[4,5-b]piridina como inhibidores duales de dyrk1/clk1 | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| CO2017007663A2 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| DK3322706T3 (da) | Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer | |
| CL2014002412A1 (es) | Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras. | |
| PH12015502248A1 (en) | 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors | |
| DK2922828T3 (da) | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| ZA201705933B (en) | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity | |
| JO3372B1 (ar) | مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية | |
| WO2014113407A3 (en) | Use of small molecule inhibitors targeting eya tyrosine phosphatase | |
| EP3551630A4 (en) | IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS | |
| DK3083627T3 (da) | [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX364859B (es) | Derivados de imidazopirazinona. | |
| EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
| EP3694521A4 (en) | TOPICAL METHOTREXATE SOLUTION FOR TREATMENT OF PSORIASIS | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| AR101915A1 (es) | Intermediarios y procesos para la preparación de compuestos |